Weekly Investment Analysts’ Ratings Changes for Alpha Tau Medical (DRTS)

Several brokerages have updated their recommendations and price targets on shares of Alpha Tau Medical (NASDAQ: DRTS) in the last few weeks:

• 7/23/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by Benchmark Co..
• 7/22/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
• 7/17/2026 – Alpha Tau Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
• 7/1/2026 – Alpha Tau Medical was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/4/2026 – Alpha Tau Medical had its price target raised by Barclays PLC from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 6/2/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.

Insider Activity

In other news, CFO Raphi Levy sold 2,270 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $14.00, for a total value of $31,780.00. Following the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,262,520. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 112,270 shares of company stock worth $1,270,923. 39.50% of the stock is owned by insiders.

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.